BioSpace News Archive

Lovelace Biomedical and Exemplar Genetics have teamed together to win a contract from the National Institutes of Health’s National Center for the Advancement of Translational Sciences, for the study of Sickle Cell Disease.

Smith & Nephew, the global medical technology business, today announces the results of the first ever prospective clinical trial to evaluate the effectiveness of repairing Horizontal Cleavage Tears, one of the most common meniscal tears affecting approximately one-third of patients with this injury.

Milestone marks advancement of second drug discovery program under the collaboration

Crescita is a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms

HSS created a Task Force to fight the opioid epidemic that has made substantial progress over the last two years- Here’s how they did it

DiamiR, a developer of innovative blood-based diagnostic tests for neurological and other diseases, announced the publication of “Brain-enriched microRNAs circulating in plasma as novel biomarkers for Rett syndrome” in PLOS ONE

The University of Maryland BioPark and Wexford Science & Technology, LLC, announced Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems, as the newest tenant in the UM BioPark’s 801 W.

Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer of Akebia, has been elected Chair of Kidney Care Partners (KCP), the nation’s largest kidney care coalition comprised of patient advocates, dialysis professionals, care providers, researchers and manufacturers.

Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with atopic dermatitis (AD).